Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary nonpolyposis colorectal cancer in Singapore

Familial Cancer

Volumn 11, Issue 2, 2012, Pages 279-289

  Wang, Vivian Wei ^a   Koh, Poh Koon ^b   Chow, Wai Leng ^a   Lim, Jeremy Fung Yen ^c  

^a Singapore Health Services   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Cost effectiveness; Genetic testing; Hereditary non polyposis colorectal cancer; Markov modeling; Surveillance

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FIRST DEGREE RELATIVE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HEALTH SURVEY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; RELATIVE; RESOURCE ALLOCATION; SINGAPORE; STATISTICAL MODEL;

COHORT STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; MALE; MARKOV CHAINS; MODELS, STATISTICAL; MUTATION; PATIENT COMPLIANCE; PUBLIC HEALTH SURVEILLANCE; SINGAPORE; YOUNG ADULT;

EID: 84864672019     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9513-y     Document Type: Article

References (52)

1. National Registry of Diseases Office of Singapore (2011) Singapore cancer registry interim annual registry report: Trends in cancer incidence in Singapore 2005-2009 Health Promotion Board Singapore. http://www.nrdo.gov.sg/ uploadedFiles/NRDO/ Cancer-Trends-Report%20-05-09.pdf. Accessed 1 August 2011
2. Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338(21): 1481-1487
3. Lamberti C, Mangold E, Pagenstecher C et al (2006) Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 74(1): 58-67
4. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919-932
5. Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114-1125
6. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71(3):677-685
7. Watson P, Riley B (2005) The tumor spectrum in the Lynch syndrome. Fam Cancer 4(3):245-248
8. Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214-218
9. Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129(2):415-421
10. Lynch HT, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology 104(5):1535-1549
11. Koh PK, Chew MH, Tan YS et al. (2010) Preliminary results of mismatch repair deficiency screening via immunohistochemical staining in young Asian colorectal cancers. In: Ling KL (ed) Proceedings of Singapore healthcare, vol 19, (1). pp 3-11
12. Ministry of Health Singapore (2010) MOH Clinical Practice Guidelines on cancer screening. http://www.moh.gov.sg/content/ dam/moh-web/Publications/ Guidelines/Clinical%20practice%20 guidelines/2010/cpg- Cancer%20Screening%20Booklet%20FINAL %20v6.pdf. Accessed 1 Aug 2011
13. Stanley AJ, Gaff CL, Aittomaki AK et al (2000) Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer (HNPCC). Med J Aust 172(7):313-316
14. Loader S, Shields C, Rowley PT (2005) Impact of genetic counseling and DNA testing on individuals with colorectal cancer with a positive family history: A population-based study. Genet Test 9(4):313-319
15. Lynch HT, Watson P, Shaw TG et al (1999) Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer 86(11 Suppl): 2457-2463
16. Dinh TA, Rosner BI, Atwood JC et al. (2011) Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila) 4(1): 9-22
17. Kievit W, de Bruin JH, Adang EM et al (2005) Cost effectiveness of a new strategy to identify HNPCC patients. Gut 54(1):97-102
18. Ramsey SD, Burke W, Clarke L (2003) An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 5(5):353-363
19. Ramsey SD, Clarke L, Etzioni R et al (2001) Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 135(8 Pt 1):577-588
20. Reyes CM, Allen BA, Terdiman JP, Wilson LS (2002) Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: Effectiveness and cost-effectiveness. Cancer 95(9):1848-1856
21. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129(10):787-796
22. Vasen HF, van Ballegooijen M, Buskens E et al (1998) A costeffectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers.Cancer 82(9):1632-1637
23. Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT (2007) Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 23(1):89-95
24. Breheny N, Geelhoed E, Goldblatt J, Ee H, O'Leary P (2006) Economic evaluation of the familial cancer programme in Western Australia: Predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma. Commun Genet 9(2):98-106
25. Jenkins MA, Baglietto L, Dowty JG et al (2006) Cancer risks for mismatch repair gene mutation carriers: A population-based early onset case-family study. Clin Gastroenterol Hepatol 4(4):489-498
26. Altekruse SF, Kosary CL, Krapcho M et al. (2010) SEER cancer statistics review 1975-2007 National Cancer Institute. http://seer.cancer.gov/csr/1975- 2007/. Accessed 1 August 2011
27. Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108(5):1405-1411
28. Wagner J, Tunis S, Brown M, Ching A, Almeida R (1996) Costeffectiveness of colorectal cancer screening in average-risk adults. In: Young G, Rozen P, Levin B (eds) Prevention and early detection of colorectal cancer. Saunders, London, pp 321-356
29. Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329(27):1977-1981
30. Winawer SJ, Zauber AG, O'Brien MJ et al (1993) Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 328(13):901-906
31. Vasen HF, Mecklin JP, Watson P et al (1993) Surveillance in hereditary nonpolyposis colorectal cancer: An international cooperative study of 165 families. The International Collaborative Group on HNPCC. Dis Colon Rectum 36(1):1-4
32. Wong SS, Leong AP, Leong TY (2004) Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: A dynamic decision analytic approach. Stud Health Technol Inform 107(Pt 1):104-110
33. Department of Statistics Singapore (2011) Key annual indicators. http://www.singstat.gov.sg/stats/keyind.html. Accessed 1 August 2011
34. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford medical publications, 3rd edn. Oxford University Press, Oxford
35. Making choices in health: WHO guide to cost-effectiveness analysis (2003). World Health Organization, Geneva.
36. Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353-362
37. Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829-834
38. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ (2000) Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 24(2):137-142
39. Bourne TH, Whitehead MI, Campbell S et al (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43(2): 92-97
40. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH (1997) Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176(2):377-380
41. Langer RD, Pierce JJ, O'Hanlan KA et al (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337(25):1792-1798
42. Lanspa SJ, Lynch HT, Smyrk TC et al (1990) Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program. Gastroenterology 98(5 Pt 1):1117-1122
43. Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29(3):160-164
44. Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29(12):849-853
45. Ministry of Health Singapore (2007) National health surveillance survey 2007. http://www.moh.gov.sg/mohcorp/uploadedFiles/ Publications/Reports/2009/ nhss2007.pdf. Accessed 1 August 2011
46. Van Bebber SL, Liang S-Y, Phillips KA et al (2007) Valuing personalized medicine: Willingness to pay for genetic testing for colorectal cancer risk. Pers Med 4(3):341-350
47. Esplen MJ, Madlensky L, Butler K et al (2001) Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 103(1):9-15
48. Kolata G (1998) Genetic testing falls short of public embrace. The New York times, 27 March 1998, p A16
49. Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281(17):1618-1622
50. Davey A, Rostant K, Harrop K, Goldblatt J, O'Leary P (2005) Evaluating genetic counseling: Client expectations, psychological adjustment and satisfaction with service. J Genet Couns 14(3): 197-206
51. Winawer SJ, Fletcher RH, Miller L et al (1997) Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 112(2):594-642
52. Sonnenberg A, Delco F, Inadomi JM (2000) Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133(8):573-584